The Hematology Clinical Research Training Program at the University of Pennsylvania was established in 1978 and has provided training for 132 men and women. The program's primary goal is to help a diverse group of individuals prepare for careers as investigators in the broadly-defined discipline of hematology and blood disorders. The faculty includes 37 trainers of all academic ranks and a plan is in place for adding or withdrawing trainers when appropriate. Up to 12 new trainees are accepted each year (8 postdocs and 4 predocs). Candidates were originally were drawn primarily from physicians enrolled in the clinical hematology training programs in the Departments of Medicine and Pediatrics. Since 1998 we have also supported postdoctoral trainees who are not physicians and, since 2004, predoctoral trainees, most of whom are in Penn's MD-PhD program. The connection to the MD-PhD program takes advantage of the PI's role as the director of that program. The inclusion of predoctoral students reflects our belief in the long term value of involving talented students to hematology-related research at an earlier point in their training as scientists and physician-scientists. Essential features of the program include formal and informal advising, skills workshops, attendance at local seminars and national conferences, coursework, training in the responsible conduct of research, and an annual symposium. MD postdoctoral fellows have the option of enrolling in a Biomedical Graduate Studies (BGS) PhD program. Outcomes. 117 postdoctoral trainees (68 MD, 17 MD-PhD and 32 PhD) and 15 pre-doctoral trainees (10 MD-PhD and 5 PhD) have been supported. Of the 109 who have completed all stages of training, 56 (50%) hold full-time appointments at an academic institution, 13 (12%) are employed in industry, 1 (1%) works at the FDA, and 3 (3%) run transfusion services at the NIH or Red Cross (total 67%), all of which we consider appropriate outcomes. Of those who currently hold fulltime academic appointments, at least 68% currently hold or have had NIH research funding. A detailed plan for attracting and training a diverse group of men and women, monitoring their progress benchmarked with an individualized development plan, and receiving feedback from trainees, alumni and faculty is included in the application.

Public Health Relevance

Hematology Clinical Research Training Program (T32 HL-07439) PI: Brass, Lawrence F. PROJECT NARRATIVE As the pace at which biomedical research advances increases, there is a greater need than ever for physician-scientists and scientists who are trained to work at the intersection between medicine and science. The goal of the Hematology Clinical Research Training Program is to identify, train and mentor a diverse group of outstanding men and women and to help them become teachers, scholars, and leaders of biomedical research in academia and industry with an emphasis on fields of endeavor that are applicable to the broad range of hematology.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
3T32HL007439-38S1
Application #
9401839
Study Section
Program Officer
Chang, Henry
Project Start
1979-07-01
Project End
2019-06-30
Budget Start
2016-12-01
Budget End
2017-06-30
Support Year
38
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brenner, Jacob S; Kiseleva, Raisa Yu; Glassman, Patrick M et al. (2018) The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series). Pulm Circ 8:2045893217752329
Bagashev, Asen; Sotillo, Elena; Tang, Chih-Hang Anthony et al. (2018) CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol Cell Biol :
Greineder, Colin F; Villa, Carlos H; Walsh, Landis R et al. (2018) Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting. Bioconjug Chem 29:56-66
Kiseleva, Raisa Yu; Glassman, Patrick M; Greineder, Colin F et al. (2018) Targeting therapeutics to endothelium: are we there yet? Drug Deliv Transl Res 8:883-902
Greineder, Colin F; Johnston, Ian H; Villa, Carlos H et al. (2017) ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model. Blood Adv 1:1452-1465
Thalji, Nabil K; Camire, Rodney M (2017) Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol 24:453-459
George, Lindsey A; Sullivan, Spencer K; Giermasz, Adam et al. (2017) Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 377:2215-2227
Zhen, Tao; Kwon, Erika M; Zhao, Ling et al. (2017) Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. Blood 130:2431-2442
Peslak, Scott A; Olson, Timothy; Babushok, Daria V (2017) Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol 18:70
Carnemolla, Ronald; Villa, Carlos H; Greineder, Colin F et al. (2017) Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB J 31:761-770

Showing the most recent 10 out of 118 publications